Center for Personalized Therapeutics

ACCOuNT Trial

The African-American Cardiovascular Pharmacogenomics Consortium (ACCOuNT) is an NIH-supported, multi-institutional group of physicians, researchers, and patients whose goal is to reduce disparity in precision medicine, particularly for African-Americans.

The ACCOuNT Translational project aims to explore the feasibility of implementing preemptive pharmacogenomic result delivery for African-Americans in the inpatient setting across multiple institutions. 

Addressing the Racial Disparity in Precision Medicine

The African-American Cardiovascular Pharmacogenomics Consortium (ACCOuNT) is an NIH-supported, multi-institutional group of physicians, researchers, and patients whose goal is to reduce disparity in precision medicine, particularly for African-Americans.

The ACCOuNT Translational project aims to explore the feasibility of implementing preemptive pharmacogenomic result delivery for African-Americans in the inpatient setting across multiple institutions.

%

Percent of African-american population in the US

Age-Adjusted Rate of cancer death per 100,000 African-american in 2018

%

Percent of african-american Reports Being unfairly Treated when receiving health care in 2020

—— “Disparities in Health and Health Care Among Black People”. The Kaiser Family Foundation 2022

Accounting for Minority Disparities in Precision Medicine

The African-American Cardiovascular Pharmacogenomics Consortium (ACCOuNT) is a dynamic group dedicated to revolutionizing precision medicine for African-Americans. Our Translational project is exploring the possibility of delivering personalized pharmacogenomic results to African-American patients during their hospital stays.

By incorporating race-specific genetic markers and recommendations into the Genomic Prescribing System (GPS), doctors, pharmacists, and other healthcare professionals can access this valuable information to make more informed treatment decisions. With self-identified African-American patients participating and cutting-edge genotyping technology at work, ACCOuNT is driving progress towards reducing healthcare disparities.

 

Our mission

The majority of pharmacogenomic (PGx) studies have been conducted on European ancestry populations, thereby excluding minority populations and impeding the discovery and translation of African American–specific genetic variation into precision medicine. Without accounting for variants found in African Americans, clinical recommendations based solely on genetic biomarkers found in European populations could result in misclassification of drug response in African American patients.

We are here to incorporate African American–specific sequence variations into clinical recommendations at the point of care using our unique web portal Genome Prescribing System (GPS).

Diversity

Incorporate race-specific SNPs and recommendations into the GPS database

Community

Create a cohort of African-American patients receiving inpatient care using the GPS.

Medical Advise

Assess race-specific recommendations via the GPS in consortium institutions.

Project Leaders

The ACCOuNT Translational project is led by principal investigator Dr. Peter O’Donnell (University of Chicago) and site leads Drs. Kevin O’Leary (Northwestern University) and Edith Nutescu (University of Illinois at Chicago).

Dr. O'Donnel Cropped

Dr. Peter O’Donnell

Principle investigator

Associate Professor of Medicine, Section of Hematology/Oncology; Chair, Committee on Clinical Pharmacology and Pharmacogenomics; Deputy Director, Center for Personalized Therapeutics, The University of Chicago

Dr. O'Donnel Cropped

Dr. Kevin O’Leary

Site Lead

Associate Vice Chair for Quality, Department of Medicine
Chief of Hospital Medicine in the Department of Medicine, John T. Clarke Professor of Medicine, Northwestern University

dr Natalie Reizine cropped

Dr. Edith Nutescu

Site Lead

Department Head, Pharmacy Practice
Professor (Tenured), Pharmacy Practice
Affiliate Faculty, Center for Pharmacoepidemiology and Pharmacoeconomic Research
Affiliate Faculty, Center for Dissemination and Implementation Science, University of Illinois at Chicago

Incorporating African-American- specific sequence variations at the point of care

Genetic biomarkers found in European populations could result in misclassification of drug response in African American patients.

With self-identified African-American patients participating and cutting-edge genotyping technology at work, ACCOuNT is driving progress towards reducing healthcare disparities in precision health care. 

 

How ACCOuNT works

Self-identified African-American patients who enroll in the ACCOuNT Translational project provide a blood sample which is sent to the Center for Personalized Therapeutics’ CLIA-certified laboratory for genotyping. Genotyping results and clinical decision support are made available within the Genomic Prescribing System (GPS). Providers who staff inpatient services (physicians, pharmacists, nurse practitioners, and physician assistants) are eligible to enroll for the ACCOuNT Translational project and access patient genotyping results and pharmacogenomic recommendations via the GPS.

Each hospital admission at which a preemptively genotyped patient is treated by an enrolled provider is evaluated. Data captured includes provider use of the GPS, as well medications prescribed or administered during the course of the admission. The primary outcome of interest is frequency of GPS use by study providers.

Reducing healthcare disparities in precision medicine for African-Americans

Generating preemptive pharmacogenomic results for African-American patients during inpatient care

Empowering providers with race-specific genetic markers and treatment recommendations.

Join us to eradicate the racial inequality in precision medicine.

For Physicians

Join our team of physicians to eradicate the gap in precision medicine. Providers who staff inpatient services are eligible to enroll for the ACCOuNT project and access patient genotyping results and pharmacogenomic recommendations via the GPS portal.

For Patients

The patients will be identified through recruitment from the inpatient medicine services who are likely to initiate, or are newly-starting, warfarin therapy. If you are interested in joining the clinical trial, please check your eligibility and contact your health provider. 

For Research

Inquire how our web-based portal GPS can be incorporated as a part of oncology care pipeline and lead the future of precision medicine and optimal cancer care.

Others

Are you passionate about driving progress toward reducing healthcare disparities? Discover more about our groundbreaking work by visiting our website or contacting us. 

Join us to eradicate the gap in precision medicine by undertaking research projects centering on DNA variant discovery in African Americans.

Phone

(773)-753-1200

Open Hours

Mon – Fri: 9:00 AM – 4PM

Address

5841 South Maryland Avenue, MC 2115